Midwest Cardiovascular Research Foundation, 1622 E. Lombard Street, Davenport, IA 52803 USA.
J Invasive Cardiol. 2021 Sep;33(9):E677-E680. doi: 10.25270/jic/20.00693.
The Venovo venous stent (BD/Bard Peripheral Vascular) is indicated to treat iliofemoral veno-occlusive disease. We present our own experience with the Venovo venous stent in treating iliac vein compression (ILVC).
In this retrospective cohort, we included consecutive patients treated with the Venovo venous stent for ILVC at our center. Stent deployment and sizing were guided by intravascular ultrasound (IVUS). Minimal luminal areas at the compression before and after treatment were measured by IVUS. Clinical improvement was determined by symptoms reported by patients and the Clinical Etiologic Anatomic and Pathophysiologic (CEAP) score. The primary safety endpoint was freedom from acute venothromboembolic disease, stent migration, perforation, acute/subacute closure, and vascular complications. The primary safety endpoint was target-lesion revascularization at 1 year.
A total of 50 consecutive patients (57 Venovo stents, 36 women, mean age, 59.8 ± 16.3 years) were included. IVUS-measured mean percent stenosis at the compression site was 64.8% ± 12.8%. Mean total stent length and diameter were 78.0 ± 54.0 mm and 17.1 ± 1.9 mm, respectively. The primary safety endpoint was met in all subjects. Procedural technical success was 100% (successful deployment with no complications). At 1 year, 83.8% of patients reported improvement in their symptoms. Freedom from total occlusion at 1 year was 100% (data available for n = 30 patients). Target-lesion revascularization (TLR) was 2% at 1 year due to 1 patient who had stent explantation from worsening ipsilateral left leg and back pain.
In this single-center experience, the Venovo venous stent was safe and effective in treating ILVC with 98% freedom from TLR at a follow-up of 1 year. Improvement in symptoms was reported in the majority of patients.
Venovo 静脉支架（BD/Bard 外周血管）用于治疗髂股静脉闭塞性疾病。我们报告了在我们中心使用 Venovo 静脉支架治疗髂静脉压迫（ILVC）的经验。
在这项回顾性队列研究中，我们纳入了在我们中心接受 Venovo 静脉支架治疗 ILVC 的连续患者。支架的放置和尺寸由血管内超声（IVUS）指导。通过 IVUS 测量治疗前后压迫处的最小管腔面积。临床改善由患者报告的症状和临床病因解剖和病理生理（CEAP）评分确定。主要安全性终点是无急性静脉血栓栓塞性疾病、支架移位、穿孔、急性/亚急性闭塞和血管并发症。主要安全性终点是 1 年时的靶病变血运重建。
共纳入 50 例连续患者（57 个 Venovo 支架，36 例女性，平均年龄 59.8 ± 16.3 岁）。IVUS 测量的压迫部位平均狭窄百分比为 64.8% ± 12.8%。支架总长度和直径的平均值分别为 78.0 ± 54.0 mm 和 17.1 ± 1.9 mm。所有患者均达到主要安全性终点。手术技术成功率为 100%（无并发症成功植入）。1 年后，83.8%的患者报告症状改善。1 年时总闭塞的无闭塞率为 100%（可获得 n = 30 例患者的数据）。1 年后，由于 1 例患者因同侧左腿和背部疼痛恶化而进行支架取出，TLR 为 2%。
在这项单中心经验中，Venovo 静脉支架在治疗 ILVC 方面是安全有效的，1 年随访时 TLR 的无闭塞率为 98%。大多数患者报告症状改善。
